Buprenorphine

FORE Awards $900,000 in New Grants to Improve Access to Lifesaving Medications for Opioid Use Disorder in Pharmacies Nationwide

Retrieved on: 
Tuesday, December 5, 2023
Policy, Risk, Houston Community College, Pharmacist, Drug, Buprenorphine, Drug Enforcement Administration, University, University of Southern California, MPH, Patient, Organization, University of Rhode Island, Howard University, Opioid use disorder, Ground substance, Nursing

To improve access to medications for opioid use disorder, the Foundation for Opioid Response Efforts (FORE) today announced $900,000 in new grants.

Key Points: 
  • To improve access to medications for opioid use disorder, the Foundation for Opioid Response Efforts (FORE) today announced $900,000 in new grants.
  • The University of Rhode Island is receiving $455,797 to train pharmacists in Connecticut and Ohio to prescribe and dispense medications for opioid use disorder.
  • These latest grants continue FORE’s work to accelerate the ability of pharmacies to provide care to patients with opioid use disorder.
  • Since its founding in 2018, FORE has awarded grants totaling $40,113,091 to address the opioid and overdose crisis.

Bicycle Health & Wellpath Collaborate to Reduce Recidivism and Overdose Deaths by Providing Injectable Buprenorphine in Federal Residential Reentry Centers for the Federal Bureau of Prisons (FBOP)

Retrieved on: 
Thursday, November 16, 2023
HOTD, Omnibus spending bill, Risk, Medication, Recidivism, Patient, FBOP, RRC, CAA, Opioid use disorder, Buprenorphine, Death, Drug, Telehealth, OUD, Nursing, Pharmaceutical industry, Wellpath

Injectable buprenorphine is a frequently prescribed form of MOUD for incarcerated adults, and Bicycle Health's clinicians can now prescribe Sublocade via telehealth for Wellpath patients.

Key Points: 
  • Injectable buprenorphine is a frequently prescribed form of MOUD for incarcerated adults, and Bicycle Health's clinicians can now prescribe Sublocade via telehealth for Wellpath patients.
  • In February 2023, Wellpath entered into an affiliation agreement with Bicycle Health to offer virtual Medication for Opioid Use Disorder (MOUD) treatment to Wellpath patients.
  • Wellpath patients receiving MOUD care with Sublocade during incarceration can now seamlessly continue their MOUD treatment without interruptions when transitioning to reentry centers (halfway houses) served by Bicycle Health.
  • The affiliation between Bicycle Health and Wellpath began in February and has provided care to over 1,000 patients residing in 122 FBOP Residential Reentry Centers (RRC) across 42 states.

DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 14, 2023
Naloxone, Fentanyl, Research, Observation, SAN, CFO, Methadone, Buprenorphine, Patient, FDA, Death, SSW, Opioid use disorder, Poisoning, Trial of the century, Rat, Society, Drug development, DMK, Management, Pharmaceutical industry

SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) --  DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products to combat the fentanyl and substance use disorder crises, today announced financial results for the third quarter ended September 30, 2023, and provided an update on recent corporate developments.

Key Points: 
  • “The change in the company name to DMK Pharmaceuticals Corporation and the new executive team are the first steps in this process.
  • The DMK research study is designed to evaluate the efficacy of ZIMHI®, intramuscular naloxone, versus the standard of care generic version of NARCAN®, intranasal naloxone.
  • Revenues for the third quarter ending September 30, 2023 were $0.0 million, compared to $1.5 million for the same period in 2022.
  • Research and development (R&D) expense for the third quarter of 2023 was $0.4 million compared to $2.0 million in the third quarter of 2022.

DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023

Retrieved on: 
Monday, November 13, 2023
Buprenorphine, SAN, Methadone, Patient, Substance abuse, Opioid use disorder, Standard of care, Rat, Society, Poster, OUD, DMK, Pharmaceutical industry

“Only about 12% of patients receive treatment for OUD, despite the proven efficacy of current medications.

Key Points: 
  • “Only about 12% of patients receive treatment for OUD, despite the proven efficacy of current medications.
  • Buprenorphine, the market leader with US sales in excess of $3B in 2022, requires an induction phase to induce withdrawal symptoms prior to initiating the first dose.
  • The positive data to be presented today marks the first step to realizing this promise,” said Eboo Versi, M.D., Ph.D., CEO of DMK Pharmaceuticals.
  • “We are excited to present preclinical data comparing DPI-125, a triple opioid agonist, to the standard of care treatments buprenorphine and methadone to alleviate withdrawal symptoms.

United States Transdermal Patch Market Report 2023: Dosage, Price & Clinical Trials Insights to 2029 - Focus on Opioid, Cardiovascular Diseases, Neurological Disorders, and Hormonal Therapy - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 23, 2023
Medical Devices, Health, Gastritis, Brown University, Transdermal patch, Research, Indication, Chronic pain, Parkinson's disease, Pain management, Buprenorphine, University of California, Davis, Pregnancy, Patient, FDA, Alzheimer's disease, Opioid use disorder, Zydus Lifesciences, University, Cancer, Communication, Pain, Growth, Nerve, DSM-IV codes, Generic drug, Pharmaceutical industry, Adhesive, Birth control

The "US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.
  • With the rapid approvals of transdermal patches lately, the FDA has also marked itself as an important player in the US market of transdermal patches.
  • The FDA provides a detailed communication on the requirements of an ideal transdermal patch, and patches that meet these are allowed entry in the regional market.
  • US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2029 Report Highlights:
    US Transdermal Patch Market Opportunity: > US$ 5 Billion By 2029
    Commercially available Patches In US Market: > 25 Patches
    Ongoing Clinical Trials Of Transdermal Patches in US: > 40 Patches
    US Transdermal Patch Clinical Trials Insight By Company, Indication & Phase

AltaPointe's Behavioral Health Crisis Center Offers Innovative Approach to Fentanyl Addiction Treatment Using Ketamine in Combination with Buprenorphine

Retrieved on: 
Thursday, November 9, 2023
BHCC, Buprenorphine, Ketamine, Heroin, Patient, Fentanyl, Chronic pain, Pharmaceutical industry, Cereal, Buprenorphine/naloxone

MOBILE, Ala., Nov. 8, 2023 /PRNewswire-PRWeb/ -- In the ongoing battle against the fentanyl epidemic, a promising new approach has emerged and AltaPointe Health is at the forefront. AltaPointe's Behavioral Health Crisis Center (BHCC) has started offering the use of ketamine to help transition a patient from fentanyl to buprenorphine (often referred to by the common brand name Suboxone), a proven addiction-treatment medicine.

Key Points: 
  • In the ongoing battle against the fentanyl epidemic, a promising new approach has emerged and AltaPointe Health is at the forefront.
  • AltaPointe's Behavioral Health Crisis Center (BHCC) has started offering the use of ketamine to help transition a patient from fentanyl to buprenorphine (often referred to by the common brand name Suboxone), a proven addiction-treatment medicine.
  • MOBILE, Ala., Nov. 8, 2023 /PRNewswire-PRWeb/ -- In the ongoing battle against the fentanyl epidemic, a promising new approach has emerged and AltaPointe Health is at the forefront.
  • AltaPointe's Behavioral Health Crisis Center (BHCC) has started offering the use of ketamine to help transition a patient from fentanyl to buprenorphine (often referred to by the common brand name Suboxone), a proven addiction-treatment medicine.

Opioid Use Disorder Market Insights, Epidemiology and Forecasts, 2019-2032: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, October 27, 2023
General Health, Pharmaceutical, Health, FDA, United Kingdom, Naltrexone, Epidemiology, Naloxone, Expert Opinion on Emerging Drugs, Therapy, Medicare, Organ donation after medical assistance in dying, Opioid use disorder, VIVITROL, Community Living Assistance Services and Supports Act, OTP, Disease, Methadone, OUD, Growth, Medicaid, COVID-19, Drug, EU4, Vaccine, Cereal, Pharmaceutical industry, Medical device, Dentistry, Health insurance, Health care, Buprenorphine, Indivior

The "Opioid Use Disorder (OUD)" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Key Points: 
  • The "Opioid Use Disorder (OUD)" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
  • The Opioid Use Disorder (OUD) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Opioid Use Disorder (OUD) market size from 2019 to 2032.
  • Opioid Use Disorder (OUD) Treatment FDA-approved drugs such as Buprenorphine, methadone, and naltrexone have proven effective in treating Opioid Use Disorder, decreasing overdose rates.
  • Which type of Opioid Use Disorder (OUD), as per severity, is the largest contributor to the Opioid Use Disorder (OUD) patient pool?

Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel Formulation of Anti-Fentanyl Monoclonal Antibody

Retrieved on: 
Wednesday, October 18, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Mass General Brigham, Buprenorphine, Opioid use disorder, Harvard Medical School, IND, Drug, McLean Hospital, Assistant, U.S. government and smoking cessation, Psychiatry, Doctor of Philosophy, Naltrexone, Methadone, Development, OUD, National Institute on Drug Abuse, NIDA, Immunoglobulin G, Research and development, Blood, Brain, Mass, Therapy, Fentanyl, Bangladesh Technical Education Board, Pharmaceutical industry

The new grant (UG3DA058544) is part of a multi-year award expected to total $14.8 million given to Cessation and McLean Hospital, a member of Mass General Brigham.

Key Points: 
  • The new grant (UG3DA058544) is part of a multi-year award expected to total $14.8 million given to Cessation and McLean Hospital, a member of Mass General Brigham.
  • Through different delivery methods, the platform can be optimized to potentially protect against overdose, reverse overdose, and treat fentanyl-related opioid use disorder (OUD).
  • “We are grateful to NIDA for their continued support of Cessation’s anti-fentanyl development programs,” said Andy Barrett, PhD, Chief Scientific Officer at Cessation Therapeutics.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Bicycle Health Partners with Override Health to Establish Patient Referral Relationship, Increasing Access to Specialists in Chronic Pain Care and Opioid Use Disorder Treatment

Retrieved on: 
Monday, October 9, 2023
Telehealth, Partnership, Perception, Bicycle, Prescription, Opioid use disorder, Brain, Buprenorphine, Veterans' affairs, Pain management, FDA, Entrepreneurship, Nervous system, UDS, Patient, Chronic pain, Psychology, OUD, ER, Dentistry, Health insurance, Nursing

BOSTON, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Bicycle Health, the nation’s largest provider of telemedicine treatment for opioid use disorder (OUD), announced plans to work with Override Health, a virtual chronic pain management clinic. The collaboration will allow Bicycle Health patients to discuss chronic pain management and connect them to pain management specialists across pain medicine, physical therapy, psychology, and pain coaching from Override Health. By that same measure, Override Health specialists who suspect pain patients may be struggling with OUD will have the option to refer those patients to Bicycle Health for evaluation.

Key Points: 
  • The collaboration will allow Bicycle Health patients to discuss chronic pain management and connect them to pain management specialists across pain medicine, physical therapy, psychology, and pain coaching from Override Health.
  • Override Health often treats patients who have not found success through traditional pain management methods like physical therapy, pain medications, and surgery.
  • Medication for opioid use disorder (MOUD) treatment is the gold standard of care for people with opioid use disorder (OUD).
  • By working with Bicycle Health, we can design care programs that better address opioid use and chronic pain,” said Jennie Shulkin JD, Co-Founder and CEO of Override Health.

Bicycle Health Commends U.S. Drug Enforcement Administration as It Extends Telemedicine Rule Through the End of 2024

Retrieved on: 
Friday, October 6, 2023
Telehealth, Buprenorphine, OUD, Patient, UDS, Public health, DEA, Health insurance, Pharmaceutical industry

Bicycle Health's remote urine drug screening (UDS) program has a falsification rate of less than 3% , compared to published norms of 5 to 18% for in-person treatment programs.

Key Points: 
  • Bicycle Health's remote urine drug screening (UDS) program has a falsification rate of less than 3% , compared to published norms of 5 to 18% for in-person treatment programs.
  • “The Public Health Emergency waivers have allowed us to make dramatic improvements in the way medical care for opioid use disorder is delivered," said Dr. Brian Clear, Chief Medical Officer at Bicycle Health.
  • Despite this, in February 2023, the DEA proposed a ruling that would only further limit telemedicine prescribing of medications like buprenorphine.
  • The DEA listened – extending its flexible telemedicine prescribing and convening the agency’s first Listening Sessions on this topic in September 2023, in which Dr. Clear participated .